Skip to main
GRI
GRI logo

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc is focused on developing innovative therapies for serious immune-related diseases, with promising results from their candidate GRI-0124 in murine models, showing improved overall survival and significant control over lupus nephritis, which may enhance prospects for Phase 3 clinical development. The company's strategic patient population identification could strengthen clinical outcomes and regulatory submissions, increasing the likelihood of successful trial results. Furthermore, the current valuation appears attractive based on a net present value analysis, indicating considerable upside potential as the company continues to progress with its promising therapeutic candidates in the fields of autoimmune disorders and cancer treatment.

Bears say

GRI Bio Inc. faces a negative outlook due to several fundamental financial challenges, including depressed forward multiples attributed to market volatility and uncertainty regarding the efficacy of its clinical candidates—particularly in relation to the functioning of dNKT cells in systemic lupus erythematosus (SLE) patients. The company's net loss of $2.1 million per share indicates financial strain, which could be exacerbated by the need for additional funding to support its multiple development programs and potential regulatory hurdles that may delay product advancement. Furthermore, concerns regarding failed clinical trials, the risk of dilutive capital raises, and the overall lack of commercial success present significant obstacles that may affect GRI Bio’s future viability in the biotech sector.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Jul 3, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.